1 Li, Q. et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med.382, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).
2 Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med.382, 727-733, doi:10.1056/NEJMoa2001017 (2020).
3 Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
4 Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature579, 265-269, doi:10.1038/s41586-020-2008-3 (2020).
5 Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol5, 536-544, doi:10.1038/s41564-020-0695-z (2020).
6 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA323, 1239-1242, doi:10.1001/jama.2020.2648 (2020).
7 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med.382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
8 Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat Immunol19, 108-119, doi:10.1038/s41590-017-0022-x (2018).
9 Goh, C., Narayanan, S. & Hahn, Y. S. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev255, 210-221, doi:10.1111/imr.12084 (2013).
10 Bueno, V., Sant'Anna, O. A. & Lord, J. M. Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease. Age (Dordr)36, 9729, doi:10.1007/s11357-014-9729-x (2014).
11 Garg, A. & Spector, S. A. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis209, 441-451, doi:10.1093/infdis/jit469 (2014).
12 Fang, Z. et al. Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. J Immunol195, 4873-4883, doi:10.4049/jimmunol.1501362 (2015).
13 Dominguez, C., McCampbell, K. K., David, J. M. & Palena, C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight2, e94296, doi:10.1172/jci.insight.94296 (2017).
14 Zhang, X. et al. Viral and host factors related to the clinical outcome of COVID-19. Nature583, 437-440, doi:10.1038/s41586-020-2355-0 (2020).
15 Li, S. et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight5, e138070, doi:10.1172/jci.insight.138070 (2020).
16 Bordoni, V. et al. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19. Clin. Infect. Dis., ciaa577, doi:10.1093/cid/ciaa577 (2020).
17 Agrati, C. et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ.27, 3196-3207, doi:10.1038/s41418-020-0572-6 (2020).
18 Schulte-Schrepping, J. et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell182, 1419-1440, doi:10.1016/j.cell.2020.08.001 (2020).
19 Silvin, A. et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell182, 1401-1418, doi:10.1016/j.cell.2020.08.002 (2020).
20 Zhou, R. et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity53, 864-877, doi:10.1016/j.immuni.2020.07.026 (2020).
21 Falck-Jones, S. et al. Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity. medRxiv, doi:10.1101/2020.09.08.20190272 (2020).
22 Rendeiro, A. F. et al. Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression. medRxiv, doi:10.1101/2020.09.08.20189092 (2020).
23 Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun7, 12150, doi:10.1038/ncomms12150 (2016).
24 Young, B. E. et al. Viral dynamics and immune correlates of COVID-19 disease severity. Clin. Infect. Dis., ciaa1280, doi:10.1093/cid/ciaa1280 (2020).
25 Chi, Y. et al. Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. J Infect Dis222, 746-754, doi:10.1093/infdis/jiaa363 (2020).
26 Yang, Y. et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J. Allergy Clin. Immunol.146, 119-127, doi:10.1016/j.jaci.2020.04.027 (2020).
27 Lang, S. et al. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets. Clin. Cancer Res.24, 4834-4844, doi:10.1158/1078-0432.CCR-17-3726 (2018).
28 Matsumura, T. et al. Interferon-gamma-producing immature myeloid cells confer protection against severe invasive group A Streptococcus infections. Nat. Commun.3, 678, doi:10.1038/ncomms1677 (2012).
29 Matsumura, T. et al. Sequential Sensing by TLR2 and Mincle Directs Immature Myeloid Cells to Protect against Invasive Group A Streptococcal Infection in Mice. Cell Rep.27, 561-571, doi:10.1016/j.celrep.2019.03.056 (2019).
30 Matsumura, T. & Takahashi, Y. The role of myeloid cells in prevention and control of group A streptococcal infections. Biosaf Health2, 130-134, doi:10.1016/j.bsheal.2020.05.006. (2020).
31 Ioannou, M. et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol188, 1136-1146, doi:10.4049/jimmunol.1101816 (2012).
32 Dilek, N., Vuillefroy de Silly, R., Blancho, G. & Vanhove, B. Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol3, 208, doi:10.3389/fimmu.2012.00208 (2012).
33 Esher, S. K., Fidel, P. L., Jr. & Noverr, M. C. Candida/Staphylococcal Polymicrobial Intra-Abdominal Infection: Pathogenesis and Perspectives for a Novel Form of Trained Innate Immunity. J Fungi (Basel)5, 37, doi:10.3390/jof5020037 (2019).
34 Iyer AS et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv, doi:10.1101/2020.07.18.20155374 (2020).
35 Horby, P. et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N. Engl. J. Med., doi:10.1056/NEJMoa2021436 (2020).
36 Biran, N. et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol2, e603-e612, doi:10.1016/S2665-9913(20)30277-0 (2020).
37 Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol2, e474-e484, doi:10.1016/S2665-9913(20)30173-9 (2020).
38 Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A117, 10970-10975, doi:10.1073/pnas.2005615117 (2020).
39 Fidel, P. L., Jr. & Noverr, M. C. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? mBio11, e00907-00920, doi:10.1128/mBio.00907-20 (2020).
40 Ministry of Health, Labour and Welfare, Japan. COVID-19 medical guideline https://www.mhlw.go.jp/content/000668291.pdf (2020).